Mass spectrometry quantitation of P450 isoforms in hepatocytes
AssigneeDH Technologies Development Pte. Ltd.
InventorsBrian L. Williamson, Subhasish Purkayastha
Life of this patent
Estimating the term…
Abstract
A method for screening a drug for cytochrome P450 (CYP) induction is provided and can include incubating the drug with a microsome-containing biological sample and then quantitating at least one cytochrome P450 isoform. The isoforms can be selected from 2B6, 3A4, 1A2, and 3A5 isoforms. In some embodiments, the method uses liquid chromatography tandem mass spectrometry (LC-MSMS). A quantitated value can be compared to a threshold value and the drug can be determined to exhibit an acceptable CYP induction potential when the quantitated value does not exceed the threshold value. Isolated peptides are also provided.
Claims5
A method for determining an amount of cytochrome P450 (CYP) 2B6 in a sample, said method comprising:
- subjecting said sample to an analysis with a liquid chromatography tandem mass spectrometer system, said system comprising a triple quadrupole instrument and Multiple Reaction Monitoring (MRM),
- said analysis comprising detecting a peptide having the amino acid sequence of SEQ ID NO:
- 2 by monitoring a precursor-product ion pair transition having an m/z value of about 494/777, 494/437, or 494/874 in said system and processing data from said monitoring to determine said amount.
A method for screening a drug for cytochrome P450 (CYP) induction, comprising:
- incubating the drug with a microsome-containing biological sample;
- determining a quantitated value of quantitating CYP 2B6 isoform in said drug incubated with the microsome-containing biological sample, said determining comprising,
- subjecting said drug incubated with the microsome-containing biological sample to an analysis with a liquid chromatography tandem mass spectrometer system, said system comprising a triple quadrupole instrument and multiple reaction monitoring, said analysis comprising detecting a peptide SEQ ID NO:2 by monitoring a precursor-product ion pair transition at 494/777, 494/437 or 494/784 in said system and processing data from said monitoring to determine said quantitated value;
- comparing the quantitated value to a threshold value;
- determining that the drug has an acceptable CYP induction potential when the quantitated value does not exceed the threshold value.
Dependencies are inferred from the claim text.